{"entity":{"id":"psmd3","kind":"target","name":"PSMD3","aka":["proteasome 26S subunit, non-ATPase 3","26S proteasome non-ATPase regulatory subunit 3","S3","P58","Rpn3","TSTA2"],"tldr":"PSMD3 (26S proteasome non-ATPase regulatory subunit 3) is a gene. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma and Mantle cell lymphoma.","summary":"Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair.\n\nOpen Targets scores its association with cancer at 0.63 (direct and indirect evidence; datatypes literature 0.90, genetic association 0.00, clinical 0.99).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:9560","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9560"},{"label":"UniProt O43242","url":"https://www.uniprot.org/uniprotkb/O43242/entry"},{"label":"NCBI Gene 5709","url":"https://www.ncbi.nlm.nih.gov/gene/5709"},{"label":"Ensembl ENSG00000108344","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000108344"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["multiple-myeloma","non-hodgkin-lymphoma","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.99. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"PSMD3","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:9560","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9560","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt O43242","url":"https://www.uniprot.org/uniprotkb/O43242/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000108344","url":"https://platform.opentargets.org/target/ENSG00000108344/associations","note":"association with cancer (MONDO_0004992) 0.63; per-cancer scores at or above 0.5: plasma cell myeloma 0.60, non-Hodgkin lymphoma 0.57, mantle cell lymphoma 0.54 (GraphQL API, CC0)"}],"specificity":"broadly-expressed","distribution":"few-types","specificityNote":"Broadly expressed or essential: HPA lists PSMD3 among essential proteins; a medicine acting on the wild-type protein would expose normal tissue too. HPA PSMD3: RNA tissue enhanced (skeletal muscle 242 nTPM); high antibody staining in 20 normal tissues; highest cancer staining head and neck cancer (4 of 4 high). Distribution: 2 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (plasma cell myeloma, mantle cell lymphoma). (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas PSMD3 tissue","url":"https://www.proteinatlas.org/ENSG00000108344-PSMD3/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000108344 associations","url":"https://platform.opentargets.org/target/ENSG00000108344/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:9560","ensembl":"ENSG00000108344","uniprot":"O43242","entrez":"5709","firstDescribed":1997,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Kominami et al, Mol. Biol. Cell, 1997, \"Yeast counterparts of subunits S5a and p58 (S3) of the human 26S proteasome are encoded by two multicopy suppressors of nin1-1\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/9017604/","biology":"Component of the 26S proteasome, a multiprotein complex involved in the ATP-dependent degradation of ubiquitinated proteins. This complex plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins, which could impair cellular functions, and by removing proteins whose functions are no longer required. Therefore, the proteasome participates in numerous cellular processes, including cell cycle progression, apoptosis, or DNA damage repair. Locus 17q21.1 (HGNC).","whereFound":["Multiple myeloma: Open Targets association 0.60 with plasma cell myeloma (MONDO_0009693)","Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908)","Mantle cell lymphoma: Open Targets association 0.54 with mantle cell lymphoma (MONDO_0018876)"],"targetClass":"other","prevalence":[]},"route":"/targets/psmd3/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}